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Introduction
Drug development for human cancer is a lengthy and costly
business, and many potentially promising therapeutics never
make it to the clinic – yet in breast cancer, the past 10 to
15 years have seen the introduction of several new cytotoxic
agents (paclitaxel, docetaxel, capecitabine and vinorelbine),
two new classes of endocrine therapies (the aromatase
inhibitors letrozole, anastrozole and exemestane; and the pure
oestrogen receptor (ER) antagonist fulvestrant), and most
recently targeted biological therapies against the human
epidermal growth factor receptor-2 (HER2) growth factor
receptor (trastuzumab, lapatinib) and vascular endothelial
growth factor (bevacizumab). For each drug, the clinical
development process has spanned a minimum of 10 to
15 years, culminating in large expensive pivotal registration
trials, each costing millions of dollars in research and
development expenditure.
While the incremental benefit provided by each new therapy
in advanced breast cancer may be relatively small, three of
these therapies (taxanes, aromatase inhibitors, trastuzumab)
have now been incorporated into adjuvant therapies in early
breast cancer where they are likely to make a much greater
impact on survival in this disease. While these are indeed
notable success stories, the challenges now faced by the
next generation of molecularly targeted therapeutics are
substantial.
Principles for successful drug development
with targeted therapies
To date the most significant developments in the systemic
treatment of breast cancer have been from therapies targeted
against the ER and HER2. Their development pathway has
been lengthy, however, with several decades passing from
the first discovery of the ER, and then HER2, to the results of
large-scale adjuvant trials in appropriate patients that
demonstrated improved overall clinical outcomes [1-3].
Despite this timescale, however, the key principles that have
underpinned their eventual successful development need to
be understood, as these remain highly relevant to modern
targeted therapies.
Firstly, it is crucial to show that any gene or protein product
for any potential new target is implicated in the pathogenesis
of the disease. Not only may this be as a significant
prognostic factor, but also as predictive factor such that
inhibiting or neutralising the function of the given gene/
protein product will yield a significant anti-cancer effect.
Secondly, a robust and reliable assay needs to be estab-
lished to measure expression of the target in human breast
carcinomas, and this assay needs to be easily reproducible to
good laboratory practice standards in routine pathology
laboratories. Thirdly, the targeted therapeutic that is
developed needs to specifically and selectively inhibit the
target, and as such needs to have a significant anti-cancer
effect on the cell (whether it be to inhibit cell proliferation, to
induce apoptosis or to enhance sensitivity to other conco-
mitant therapies), in addition to an acceptable toxicity profile.
For both endocrine therapies that target the ER, and trastu-
zumab that targets HER2, each of these three fundamental
principles has been adhered to.
Subsequently, it is important that any clinical trials conducted
with a targeted therapy demonstrate a significant clinical
benefit within an appropriate population of patients. Indeed, if
the target is relevant to the disease and the appropriate
patients are correctly selected, then the number needed to
treat in order to detect a significant effect within a rando-
mised phase II/III clinical trial can be relatively small. This was
most clearly seen in the pivotal clinical trial of trastuzumab in
HER2-positive metastatic disease in which only 145 patients
were needed to show both a highly significant progression-
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free survival and overall survival benefit for the addition of the
monoclonal antibody to paclitaxel chemotherapy as first-line
therapy [4]. Likewise, the adjuvant benefit now seen with the
appropriate use of tratsuzumab in the targeted population
represents a greater than 50% reduction in the residual risk
of recurrence, with an overall survival benefit [5]. Never-
theless, even in selected patients with HER2-positive disease
and using a targeted agent, about one-half of patients do not
respond – which reflects the complexity of breast cancer.
In contrast, when patients in whom the tumour does not
express the relevant target are treated with a molecularly
targeted agent, objective response rates are notably disap-
pointing. These disappointing rates were demonstrated
recently in the EGF30001 trial of lapatinib, a small-molecule
tyrosine kinase inhibitor that targets HER2. It was initially
thought that the drug also had significant clinical activity
against epidermal growth factor receptor (EGFR), so this trial
was established in the first-line metastatic setting for patients
with HER2-negative (or unknown) breast cancer [6]. In total
579 patients were randomised to receive 3-weekly paclitaxel
with either lapatinib 1,500 mg daily or placebo. A pre-planned
retrospective evaluation of HER2 by fluorescence in situ
hybridisation identified 86 patients with HER2-positive
disease – in this small subgroup, treatment with paclitaxel–
lapatinib resulted in a statistically significant improvement in
time to disease progression, objective tumour response and
clinical benefit rate. No benefit whatsoever was seen in the
HER2-negative group, and no benefit was seen in those
patients subsequently analysed for EGFR overexpression [7].
This study has demonstrated very clearly that when the most
appropriate patients are selected for a targeted therapy,
benefit can be clearly seen in a relatively small number of
patients – yet within a wider population who do not express
the target within their tumour, these patients have very little to
gain from the therapeutic in question.
Issues for clinical trial design of targeted
therapies
For clinical trials with modern targeted therapies it is there-
fore clear that one size does not fit all, and as such the
previous approach involving a classical phase I, phase II,
phase III series of trials in unselected patients with metastatic
breast cancer is inappropriate.
Once a novel targeted therapy has been developed and has
shown promise in various preclinical models, early-phase
clinical trials need to be designed to incorporate proof-of-
concept studies that clearly demonstrate the target is being
identified within tumour samples, and that a biological effect
is occurring following drug exposure in vivo. Early phase I
trials need to establish the toxicity profile, the maximum
tolerated dose and the recommended dose for phase II
studies. Subsequent extension phase Ib/IIa trials need to be
conducted in appropriate tumour types with pharmaco-
dynamic endpoints incorporated into the design.
Whether it be tumour or surrogate tissues that are sampled,
establishing that the targeted therapeutic is having an effect
on the relevant pathways is an important aspect of modern
drug development programmes for molecularly targeted
therapies. Recently this was clearly demonstrated in breast
cancer, with the development of the poly(ADP-ribose) poly-
merase inhibitor olaparib in a landmark phase I trial, whereby
patients with BRCA1 or BRCA2 mutations were enrolled [8].
In this trial, pharmacodynamic studies confirmed poly(ADP-
ribose) polymerase inhibition in tumour tissue and in
surrogate samples of peripheral blood mononuclear cells and
plucked eyebrow-hair follicles, and the trial showed that anti-
tumour activity was restricted to those mutation carrier
patients. These results from a small but very detailed phase I
trial have now allowed a rapid development programme to be
followed in the most appropriate population of patients.
Molecular profiling of breast cancer
Once a targeted therapeutic has entered phase II/III develop-
ment, it remains important to continue evaluation of those
patients who derive maximum benefit from the drug. While a
novel targeted therapy may have been developed against a
growth factor receptor that can be readily be identified by
immunohistochemitry or fluorescence in situ hybridisation
assays, additional activating mutations either within the target
or in associated downstream modulators may account for
response or resistance to the targeted therapy in question.
This has been most clearly demonstrated with the anti-EGFR
tyrosine kinase inhibitors in nonsmall-cell lung cancer, where-
by response to gefitinib is restricted to those with activating
EGFR mutations [9] or with increased gene copy number
[10]. Likewise in colorectal cancer, the presence of activating
downstream KRAS mutations is associated with resistance to
the anti-EGFR monoclonal antibody cetuximab, such that
testing for this mutation is now recommended so that only
those with wild-type KRAS are treated with cetuximab [11].
While overexpression of a given oncogene may identify the
best group of patients to treat with a novel targeted
therapeutic, only a proportion will probably therefore gain
benefit because of other co-existing mutations and molecular
alterations that will determine response/resistance to
inhibition of the key target (for example, either loss of the
PTEN tumour suppressor gene or activating mutation of
phosphatidylinositol 3-kinase (PI3K) may modulate response
to trastuzumab in HER2-positive breast cancer). Translational
studies in samples from treated patients will therefore remain
crucial in optimising clinical benefit from these new therapies.
Molecular profiling of tumours is now central to all clinical
development programmes for novel targeted therapies, and
as such this should further refine and speed up the drug
development process as well as provide a more cost-effective
approach – both in terms of initial research and development
spend but also in ensuring that, once licensed, only those
patients who will benefit from the drug are offered it. This iswell illustrated by the clinical development of mammalian
target of rapamycin (mTOR) inhibitors in breast cancer.
Following early preclinical promise that these agents may
enhance responsiveness to endocrine therapy in ER-positive
breast cancer, a large randomised phase III trial of the mTOR
inhibitor temsirolimus plus letrozole versus letrozole alone
was undertaken in over 1,000 unselected ER-positive
postmenopausal women with advanced breast cancer. The
trial was halted early because of lack of benefit [12]. The
inability to identify patients in whom the tumours may
demonstrate dependence on the PI3K/Akt/mTOR pathway
being activated may have limited the likelihood of success for
this large trial in advanced breast cancer. At a molecular level,
concern has also been expressed that mTOR inhibition may
release the negative feedback loop via S6kinase and IRS-1
[13], which then enhances further Akt activation and thus
overcomes the effects of mTOR inhibition.
An alternative clinical approach to understand which patients
may benefit from mTOR inhibition when combined with
aromatase inhibitors has been to study biomarker changes in
vivo in the preoperative neoadjuvant setting. In a randomised
phase II trial in 270 postmenopausal women with ER-positive
primary operable breast cancer (>2 cm in size), the combina-
tion of letrozole 2.5 mg/day and oral everolimus 10 mg/day
for 4 months presurgery resulted in a significantly greater
tumour shrinkage as judged by ultrasound (58% vs. 47%,
P = 0.03), as well as by clinical and mammographic assess-
ment [14]. Associated correlative science studies were then
conducted to determine those tumours most likely to respond
to combined mTOR antagonists and an aromatase inhibitor.
In particular, elevated levels of one of the downstream bio-
markers of mTOR activation (pS6240 kinase) was associated
with a greater chance of response to the combination, while
specific mutations in PIK3CA were found to be associated
with a greater likelihood of an antiproliferative response to the
combination of an mTOR antagonist plus letrozole, especially
mutations in the small in the allosteric helical domain of
exon 9. These types of neoadjuvant studies in primary breast
cancer may therefore yield informative and predictive
biomarker data that can help select appropriate patients for
future clinical trials.
Future studies should therefore make a greater effort to
enrich their trial population with the most appropriate patients –
namely those who have a tumour molecular profile likely to
predict benefit from targeting the given pathway. In the
absence of the ability to identify the molecular target in
samples of metastatic disease (that is, only the original
primary tumour is available, as often is the case), under-
standing the inherent biology in the primary tumour that
accounts for relapse/resistance may become crucial is
determining which population to select for these studies.
Genomic profiling in ER-positive breast cancer may help
identify those more likely to develop resistance to endocrine
therapy, or indeed the pathways that these tumours are most
likely to utilise as escape mechanisms, which in turn may
guide appropriate selection of target therapies to add in at
the time of relapse. Clustering tumours together based on
oncogenic pathway signatures helps determine both the
biology of the disease and the likely response patterns to
current conventional therapies [15]. Recent studies have
started to show common oncogenic pathways that intrinsic
subtypes of breast cancer will utilise, thus allowing strategies
to be developed for combinations of various signalling agents
to be utilised in an attempt to enhance responsiveness to
current therapies [16]. In particular, in ER-positive breast
cancer, gene expression profiling has identified in the luminal
B subtype that activation of growth factor signalling pathways
occurs, often independent of HER2 overexpression, thus
contributing to their poorer prognosis [17]. Selection of this
subgroup for future combination strategies may yield answers
faster than treating a more heterogeneous unselected group
of patients with ER-positive breast cancer.
Future directions with novel targeted
therapeutics
There are now a multitude of targeted therapeutics in various
stages of clinical development for breast cancer, all based on
a rationale that the target in question is valid in the patho-
genesis of the disease. While the integration of these
therapies with conventional therapeutics has been pioneered
by the combination of trastuzumab with chemotherapy, there
has been substantial research into combining targeted thera-
peutics with endocrine therapy to enhance responsiveness
and delay resistance [18]. As discussed elsewhere, progress
with integrating growth factor receptor tyrosine kinase
inhibitors or mTOR antagonists with endocrine therapies has
had mixed results in the clinic.
The emphasis is now shifting to targeting networks and path-
ways with combinations of signalling drugs, either in parallel
(so-called combined horizontal blockade) or in series (com-
bined vertical blockade). Selection of which approach is valid
depends on key preclinical studies that need to be undertaken
in various relevant models, in order to guide which combi-
nations need testing in early-phase clinical trials. Recent pre-
clinical examples of horizontal blockade in breast cancer include
mitogen-activated protein kinase kinase (MEK) inhibition
combined with PI3K in basal-like breast cancers [19], while
vertical blockade includes enhancing responsiveness to HER2-
directed therapies (trastuzumab, pertuzumab or lapatinib) by
combination with a potent PI3K inhibitor [20]. Such preclinical
data must then help drive the appropriate early phase I
combination studies to be evaluated – studies which if well
tolerated and active, as determined by relevant pharmaco-
dynamic endpoints, need to rapidly be tested in phase II studies
utilising enrichment strategies to select for the most appropriate
breast cancer phenotypes. This will ensure rapid and efficient
transition from proof-of-concept studies into pivotal efficacy
studies, thus maximising the likelihood of success.
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Drug development for breast cancer is entering a new phase
whereby the number of novel therapeutics available for study
will be larger than ever, with an even greater complexity to the
clinical and scientific questions being asked. Careful con-
sideration is needed so that several key principles are
adhered to, with greater emphasis on preclinical rationale and
understanding the biology, real-time molecular profiling and
appropriate patient selection, and intelligent clinical trial
design that will address the question posed by the novel
therapeutic being developed. While the challenges are
immense, the opportunities afforded by targeted therapies
are enormous – as such, both the pharmaceutical industry
and academic investigators have a duty to ensure that we
maximise their potential.
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